VVD-130037 manufacturers
- VVD-130037
-
- $64.00
-
2026-07-27
- CAS:3034880-93-5
- Purity: 99.92%
- Supply Ability: 10g
|
| | VVD-130037 Basic information |
| Product Name: | VVD-130037 | | Synonyms: | VVD-130037;1-[(3R)-3-[3-(4-aminopyrimidin-2-yl)-5-chlorophenyl]-1,4-oxazinan-4-yl]prop-2-en-1-one;VVD-130037 ( BAY-3605349 );2-Propen-1-one, 1-[(3R)-3-[3-(4-amino-2-pyrimidinyl)-5-chlorophenyl]-4-morpholinyl]- | | CAS: | 3034880-93-5 | | MF: | C17H17ClN4O2 | | MW: | 344.8 | | EINECS: | | | Product Categories: | (R)-1-(3-(3-(4 | | Mol File: | 3034880-93-5.mol |  |
| | VVD-130037 Chemical Properties |
| Boiling point | 529.845±50.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.318±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | form | Solid | | pka | 4.041±0.10(predicted) | | color | White to off-white |
| | VVD-130037 Usage And Synthesis |
| Uses | VVD-130037 (BAY-3605349) is an orally active covalent activator of KEAP 1 (Kelch-like ECH-associated protein 1) with anti-tumor activity. VVD-130037 degrades NRF2 (nuclear factor-erythroid 2 p45-related factor 2), resulting in significant inhibition of tumor growth in advanced solid tumors[1][2][3]. | | References | [1] Chan Shan, et al. The Crosstalk between Autophagy and Nrf2 Signaling in Cancer: from Biology to Clinical Applications. Int J Biol Sci. 2024 Nov 11;20(15):6181-6206. DOI:10.7150/ijbs.103187
[2] Gu X, et al. The Cancer Antioxidant Regulation System in Therapeutic Resistance. Antioxidants (Basel). 2024 Jun 27;13(7):778. DOI:10.3390/antiox13070778
[3] Han B, et al. Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer. Cell Rep. 2024 Jul 23;43https://pubmed.ncbi.nlm.nih.gov/39003742/(7):114507. DOI:10.1016/j.celrep.2024.114507 |
| | VVD-130037 Preparation Products And Raw materials |
|